

www.grangergenetics.com

601 Biotech Dr.Suite 301 Richmond, VA 23235

Specimen Information

Date Collected: 06/02/2022

06/03/2022 16:04 Date Received:

06/07/2022 12:00 Date Reported:

AAS22-3003-0001658

Specimen Type: Serum

Sex: Male

Age: 66

Phone:

Fax:

Patient Information

TESTING

TESTPRACTICECREATEDON0826

123 NOWHERE STREET

Phone: 804-965-9225 804-545-1686 ANYWHERE CITY, VA 23294 Fax:

Physician Information

CPT Codes: 82657 x2, 83516.

Test Patient

Date of Birth: 12/07/1955

Requisition #: test6322

Asparaginase-Drug UnSpecified Results

Patient MRN: Sample ID:

Calibration of the asparaginase assay is dependent on the exact formulation of L-asparaginase administered to the patient.

(844) 347-2643

(804) 977-5042

ACTIVITY

Name:

If the administered drug was Asparlas, the asparaginase activity is: 0.906 IU/mL

If the administered drug was Erwinaze, the asparaginase activity is: 1.262 IU/mL

0.923 IU/mL If the administered drug was Oncaspar, the asparaginase activity is:

If the administered drug was Rylaze, the asparaginase activity is: 1.092 IU/mL

ANTIBODIES

Not Detected Asparaginase-Antibodies are:

Assay Methodologies and Limitations of Asparaginase-Drug UnSpecified™

Asparaginase Enzyme Activity Quantification Assay utilizes a spectrophotometry/absorbance-based enzyme-coupled kinetic reaction. Measurements of unknown samples are made against a standard curve generated from E. coli L-asparaginase with each run. Calculations for Rylaze®, Erwinaze® and Oncaspar® were empirically derived and utilize a correction factor that has been correlated to the E. coli L-asparaginase activity. Asparaginase concentrations can vary widely from patient to patient there is no reference range for this assay.

The Asparaginase antibody assay is an ELISA based assay and is only intended to report the presence or absence of antibodies against Asparaginase. This assay does not specifically identify neutralizing antibodies. Antibodies should not be present in normal human serum but may be present in patients on Asparaginase therapy.

These tests were developed and their performance characteristics determined by Granger Genetics. Neither assay has been cleared or approved by the FDA. The laboratory is regulated under CLIA as qualified to perform high-complexity testing. This test is used for clinical purposes. It should not be regarded as investigational or for research.

Medical Director: David G. Bostwick, M.D., M.B.A. Page 1 of 1